Matches in SemOpenAlex for { <https://semopenalex.org/work/W1592414132> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W1592414132 abstract "In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%. Continuous infusion of these drugs is on many grounds theoretically attractive and may therefore offer advantages over bolus or short-term infusion.Sixteen patients with advanced adenocarcinoma of the pancreas with progressive measurable disease and no previous chemotherapy entered the study. After implantation of a subcutaneous infusion chamber patients were treated on days 1-12 with ifosfamide (1.0 g/m2/day) and 5-FU (300 mg/m2/day) as a continuous intravenous infusion using a portable infusion pump. Mesna (1.0 g/m2/day) was added as uroprotective agent from day 1-14. Courses were repeated every 4 weeks.Fifteen of the 16 patients were evaluable for response. One partial response was observed (response rate 7% [95% CI: 0%-32%]). Toxicity occurred in 64% of the courses. Dose limiting toxic effects were grade 3 nausea/vomiting (WHO) in 3 patients, grade 2 mucositis in 1 patient and grade 4 leukopenia in 1 patient.Intermittent continuous infusion with ifosfamide, mesna and 5-FU is feasible on an outpatient basis. Although continuous infusion of ifosfamide may have a more favorable toxicity profile, the combination of 5-FU and ifosfamide in this schedule is no more effective than bolus or short-term infusion." @default.
- W1592414132 created "2016-06-24" @default.
- W1592414132 creator A5019169025 @default.
- W1592414132 creator A5038071721 @default.
- W1592414132 creator A5055804087 @default.
- W1592414132 creator A5061082016 @default.
- W1592414132 creator A5064365510 @default.
- W1592414132 creator A5065480132 @default.
- W1592414132 creator A5072059085 @default.
- W1592414132 creator A5082755452 @default.
- W1592414132 date "1995-12-01" @default.
- W1592414132 modified "2023-09-29" @default.
- W1592414132 title "Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas" @default.
- W1592414132 cites W1966327501 @default.
- W1592414132 cites W1995081817 @default.
- W1592414132 cites W1996370342 @default.
- W1592414132 cites W2000978440 @default.
- W1592414132 cites W2006013766 @default.
- W1592414132 cites W2051973398 @default.
- W1592414132 cites W2060765563 @default.
- W1592414132 cites W2064764897 @default.
- W1592414132 cites W2256943140 @default.
- W1592414132 cites W2407385164 @default.
- W1592414132 doi "https://doi.org/10.1093/oxfordjournals.annonc.a059070" @default.
- W1592414132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8750159" @default.
- W1592414132 hasPublicationYear "1995" @default.
- W1592414132 type Work @default.
- W1592414132 sameAs 1592414132 @default.
- W1592414132 citedByCount "5" @default.
- W1592414132 countsByYear W15924141322014 @default.
- W1592414132 countsByYear W15924141322018 @default.
- W1592414132 crossrefType "journal-article" @default.
- W1592414132 hasAuthorship W1592414132A5019169025 @default.
- W1592414132 hasAuthorship W1592414132A5038071721 @default.
- W1592414132 hasAuthorship W1592414132A5055804087 @default.
- W1592414132 hasAuthorship W1592414132A5061082016 @default.
- W1592414132 hasAuthorship W1592414132A5064365510 @default.
- W1592414132 hasAuthorship W1592414132A5065480132 @default.
- W1592414132 hasAuthorship W1592414132A5072059085 @default.
- W1592414132 hasAuthorship W1592414132A5082755452 @default.
- W1592414132 hasBestOaLocation W15924141321 @default.
- W1592414132 hasConcept C141071460 @default.
- W1592414132 hasConcept C2776187130 @default.
- W1592414132 hasConcept C2776694085 @default.
- W1592414132 hasConcept C2777506904 @default.
- W1592414132 hasConcept C2778119113 @default.
- W1592414132 hasConcept C2778496288 @default.
- W1592414132 hasConcept C2780376820 @default.
- W1592414132 hasConcept C2780456651 @default.
- W1592414132 hasConcept C2780873365 @default.
- W1592414132 hasConcept C42219234 @default.
- W1592414132 hasConcept C43376680 @default.
- W1592414132 hasConcept C71924100 @default.
- W1592414132 hasConceptScore W1592414132C141071460 @default.
- W1592414132 hasConceptScore W1592414132C2776187130 @default.
- W1592414132 hasConceptScore W1592414132C2776694085 @default.
- W1592414132 hasConceptScore W1592414132C2777506904 @default.
- W1592414132 hasConceptScore W1592414132C2778119113 @default.
- W1592414132 hasConceptScore W1592414132C2778496288 @default.
- W1592414132 hasConceptScore W1592414132C2780376820 @default.
- W1592414132 hasConceptScore W1592414132C2780456651 @default.
- W1592414132 hasConceptScore W1592414132C2780873365 @default.
- W1592414132 hasConceptScore W1592414132C42219234 @default.
- W1592414132 hasConceptScore W1592414132C43376680 @default.
- W1592414132 hasConceptScore W1592414132C71924100 @default.
- W1592414132 hasLocation W15924141321 @default.
- W1592414132 hasLocation W15924141322 @default.
- W1592414132 hasOpenAccess W1592414132 @default.
- W1592414132 hasPrimaryLocation W15924141321 @default.
- W1592414132 hasRelatedWork W1592414132 @default.
- W1592414132 hasRelatedWork W2034682960 @default.
- W1592414132 hasRelatedWork W2035792508 @default.
- W1592414132 hasRelatedWork W2056545621 @default.
- W1592414132 hasRelatedWork W2293550071 @default.
- W1592414132 hasRelatedWork W2331434168 @default.
- W1592414132 hasRelatedWork W2396300236 @default.
- W1592414132 hasRelatedWork W2399415578 @default.
- W1592414132 hasRelatedWork W2417748545 @default.
- W1592414132 hasRelatedWork W2466730692 @default.
- W1592414132 isParatext "false" @default.
- W1592414132 isRetracted "false" @default.
- W1592414132 magId "1592414132" @default.
- W1592414132 workType "article" @default.